Proliferation imaging to measure early cancer response to targeted therapy

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7159-7160

  Mankoff, David A ^a,b   Eary, Janet F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBON 11; GEFITINIB; THYMIDINE; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; DNA SYNTHESIS; DRUG EFFICACY; EARLY CANCER; HUMAN; LUNG CANCER; NON INVASIVE PROCEDURE; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; NEOPLASM; SCINTISCANNING;

ANIMALS; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMIDINE;

EID: 58149335440     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2233     Document Type: Note

References (12)

1. 18F]Fluorothymidine PET before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Livingston RB, Hart JS. The clinical applications of cell kinetics in cancer therapy. Annu Rev Pharmacol Toxicol 1977;17:529-43.
4. Anderson H, Bulun S, Smith I, Dowsett M. Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 2007;106:49-54.
5. Cleaver JE. Thymidine metabolism and cell kinetics. Front Biol 1967;6:43-100.
6. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-67.
7. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757-62.
8. 11C]Thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003;95:675-82.
9. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
10. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47.
11. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46:371-80.
12. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-67.